A novel bivalent albumin binder for enhanced tumor retention of a fibroblast activation protein-targeted radioligand
We developed a novel bivalent albumin binder composed of two molecules of lysine-4-(<i>p</i>-iodophenyl)butyric acid, (Lys-IPBA)<sub>2</sub>, which markedly enhanced the tumor retention of a FAP-targeted radioligand compared to Lys-IPBA. The results suggest the promising potential of (Lys-IPBA)<sub>2</sub> as a pharmacokinetic modifier of radioligands for cancer diagnosis and therapy.
Authors
- Kazuma Nakashima (ORCID: https://orcid.org/0009-0003-3462-7354)
- Masahiro Ono (ORCID: https://orcid.org/0000-0002-2497-039X)
- Hiroyuki Watanabe (ORCID: https://orcid.org/0000-0002-8873-1224)
- Keisei Yamaguchi
- Kosuke Saito (ORCID: https://orcid.org/0000-0001-9070-3575)
Institutions
- Kyoto University (JP)
Publication Details
- Journal
- Chemical Communications
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1039/d5cc05231a
- Primary Topic
- Peptidase Inhibition and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 0.00